The NHS has now chosen 138 clinical entrepreneurs to design and deliver new technological solutions and innovations in healthcare, including the appointment of five healthcare scientists working on addressing conditions such as sickle cell disease and allergic reactions.
Emergency care is now in a state of emergency as missed targets reach an all-time high, bed occupancy rates surge, and flu cases increase sharply, and health chiefs warn that patients are “dying in corridors” and the system is “on its knees”.
Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).
Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on gastrointestinal disease.
The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
AstraZeneca’s biologic Fasenra has been approved for use in Europe as an add-on maintenance treatment in patients with severe eosinophilic asthma.
NHS England has approved funding for more than 160 additional GP surgery-based clinical pharmacists able to offer expert medical advice and treatment to patients.
If so, you ought to know that the 2018 PharmaTimes Clinical Researcher of the Year – The Americas application process for teams has been made MUCH simpler this year, so if you thought you didn’t have enough time to enter, think again!
Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
European regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation.
A combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US.
MSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence.
The Medicines and Healthcare Products Regulatory Agency has issued a green light allowing Celixir to carry out a potentially pivotal Phase IIb human clinical trial with its stem cell therapy Heartcel.
Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.
